Compounds > phosfolan
Page last updated: 2024-12-05

phosfolan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

phosfolan: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13689
CHEBI ID82145
SCHEMBL ID122109
MeSH IDM0042849

Synonyms (73)

Synonym
phosphoramidic acid, n-1,3-dithiolan-2-ylidene-, diethyl ester
chj98j84ay ,
unii-chj98j84ay
phosphoramidic acid, 1,3-dithiolan-2-ylidene-, diethyl ester
phosfolan
1,2-ethanedithiol, cyclic ester with p,p-diethyl phosphonodithioimidocarbonate
american cyanamide 47031
american cyanamid 47031
(diethoxyphosphinyl)dithioimidocarbonic acid cyclic ethylene ester
ei 47031
diethyl 1,3-dithiolan-2-ylidenephosphoramidate
phospholan
ac 47031
cyclic ethylene(diethoxyphosphinothioyl)dithioimidocarbonate
imidocarbonic acid, (diethoxyphosphinyl)dithio-, cyclic ethylene ester
imidocarbonic acid, phosphonodithio-, cyclic ethylene p,p-diethyl ester
cyolane insecticide
p,p-diethyl cyclic ethylene ester of phosphonodithioimidocarbonic acid
1,2-ethanedithiol, cyclic s,s-ester with phosphonodithioimidocarbonic acid p,p-diethyl ester
epa pesticide chemical code 268300
p,p-diethyl cyclic ethylene phosphonodithioimidocarbonate
cyolane
cyclic ethylene-p,p-diethyl phosphonodithioimidocarbonate
phospholan [iso-french]
oms 646
caswell no. 268b
american cyanamid ac 47,031
phosfolan [bsi:iso]
ent 25,830
cl 47031
2-(diethoxyphosphinylimino)-1,3-dithiolane
ai3-25830
american cyanamid cl-47031
einecs 213-423-2
imidocarbonic acid, phosphonodithio-, p,p-diethyl cyclic ethylene ester
hsdb 2824
cyclic ethylene p,p-diethyl phosphonodithioimidocarbonate
n-diethoxyphosphoryl-1,3-dithiolan-2-imine
947-02-4
C19011
NCGC00255841-01
dtxcid9022285
tox21_301905
cas-947-02-4
dtxsid1042285 ,
AKOS015960698
SCHEMBL122109
phosfolan [mi]
1,3-dithiolan-2-ylidenephosphoramidic acid diethyl ester
cl-47031
ei-47031
american cyanamide-47031
diethyl n-1,3-dithiolan-2-ylidenephosphoramidate
phosfolan [iso]
ac-47031
ent-25,830
phosfolan [hsdb]
CHEBI:82145
cyalane
diethyl 1,3-dithiolan-2-ylideneamidophosphate #
2-[(diethoxyphosphinyl)imino]-1,3-dithiolane
ILBONRFSLATCRE-UHFFFAOYSA-N
1,2-ethanedithiol, cyclic s,s-ester with phosphonodithioimidocarbonic acid o,o-diethyl ester
cayolan
ci-47031
cyolane cylan
cyolan
imidocarbonic acid, phosphonodithio-, o,o-diethyl cyclic ethylene ester
phosfolan 100 microg/ml in cyclohexane
diethyl (1,3-dithiolan-2-ylidene)phosphoramidate
Q7187417
phosfolan 1000 microg/ml in acetone
STARBLD0001836

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" It is believed that the phosphonate ester configuration of EPN and Leptophos has a specific mode of toxic action which is mainly located at the central nervous system."( Neurotoxicity of organophosphorus insecticides Leptophos and EPN.
Ahmed, NS; El-Sebae, AH; Elamayem, MA; Soliman, SA, 1977)		0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phosphoric ester
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency44.78530.002541.796015,848.9004AID1347395; AID1347398
GLI family zinc finger 3Homo sapiens (human)Potency68.58960.000714.592883.7951AID1259369
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.04 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
gamma-aminobutyric acid
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.. gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.		1.9610amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
chlorpyrifos
Chlorpyrifos: An organothiophosphate cholinesterase inhibitor that is used as an insecticide and as an acaricide.. chlorpyrifos : An organic thiophosphate that is O,O-diethyl hydrogen phosphorothioate in which the hydrogen of the hydroxy group has been replaced by a 3,5,6-trichloropyridin-2-yl group.		2.3620chloropyridine;
organic thiophosphate		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
environmental contaminant;
insecticide;
xenobiotic
glutamine
Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.		1.9610amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
phenylphosphonothioic acid, 2-ethyl 2-(4-nitrophenyl) ester
Phenylphosphonothioic Acid, 2-Ethyl 2-(4-Nitrophenyl) Ester: An organothiophosphorus cholinesterase inhibitor that is used as an insecticide and as a acaricide.		1.9510organic phosphonate;
organothiophosphate insecticide;
phosphonic ester		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor
rhodium
Rhodium: A hard and rare metal of the platinum group, atomic number 45, atomic weight 102.905, symbol Rh.. rhodium atom : A cobalt group element atom of atomic number 45.		2.0510cobalt group element atom
leptophos
Leptophos: An organothiophosphate insecticide.. leptophos : A racemate comprising equimolar amounts of (R)- and (S)-leptophos. It is an organothiophosphate insecticide that shows neurotoxic effect in humans.. O-(4-bromo-2,5-dichlorophenyl) O-methyl phenylphosphonothioate : An organic phosphonate that is phenylphosphonothioic O,O-acid in which the hydroxy groups are substituted by methoxy and 4-bromo-2,5-dichlorophenoxy groups.		2.3620bromobenzenes;
dichlorobenzene;
organic phosphonate;
phosphonic ester
angiotensin ii
Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).		2.0610amino acid zwitterion;
angiotensin II		human metabolite
tetrachlorvinphos
Tetrachlorvinphos: An organophosphate cholinesterase inhibitor that is used as an insecticide. It has low mammalian toxicity. (From Merck Index, 11th ed)		2.3620alkenyl phosphate;
dialkyl phosphate;
organochlorine insecticide;
organophosphate insecticide;
trichlorobenzene		acaricide;
agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor
natriuretic peptide, brain
Natriuretic Peptide, Brain: A PEPTIDE that is secreted by the BRAIN and the HEART ATRIA, stored mainly in cardiac ventricular MYOCARDIUM. It can cause NATRIURESIS; DIURESIS; VASODILATION; and inhibits secretion of RENIN and ALDOSTERONE. It improves heart function. It contains 32 AMINO ACIDS.		2.0610polypeptide
ConditionIndicatedRelationship StrengthStudiesTrials
Colorectal Cancer
[description not available]		02.2110
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.2110
Rheumatoid Arthritis
[description not available]		02.1510
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		02.1510
Left Ventricular Dysfunction
[description not available]		02.0610
Cardiac Remodeling, Ventricular
[description not available]		02.0610
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0610
Cirrhosis
[description not available]		02.0610
Blood Pressure, High
[description not available]		02.0610
Cardiovascular Stroke
[description not available]		02.0610
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.		02.0610
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		02.0610
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		02.0610
Ventricular Dysfunction, Left
A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.		02.0610
Benign Neoplasms
[description not available]		02.0610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0610
Abnormalities, Drug-Induced
Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.		01.9610
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9610
Ataxia
Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.		01.9510
Agricultural Worker Disease
[description not available]		01.9510